Alkermes' sleep disorder drug shows promise in early-stage study
09/04/2024 13:42
** Shares of drugmaker Alkermes ALKS.O rise 7% to $27.73
premarket
** Co says its experimental drug ALKS 2680 improved
wakefulness in patients of narcolepsy and hypersomnia in an
early-stage study
** Narcolepsy is a chronic neurological disorder that
affects the brain's ability to control sleep-wake cycles, while
hypersomnia is a state of excessive sleepiness
** Up to last close, stock down 6.5% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))